NCT04881123 - SER150 vs Placebo in Diabetic Kidney Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 18, 2021

Primary Completion Date

June 6, 2024

Study Completion Date

June 6, 2024

Conditions

Diabetic Kidney Disease

Interventions

DRUG

SER150

Dosage Level(s): 30 mg (1 capsule of 15 mg twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)

DRUG

Placebo

Dosage Level(s): Matched placebo (1 capsule twice a day - morning and evening) (except on Day 168 where participants will only receive a single dose (QD) in the morning)

Trial Locations (12)

2065

Royal North Shore Hospital, Saint Leonards

2170

Liverpool Hospital, Liverpool

3010

Pacific Clinical Research Clinic Rotorua, Rotorua

3021

Sunshine Hospital, Saint Albans

3065

St Vincent's Hospital, Fitzroy

3200

Lakeland Clinical Trials Waikato, Hamilton

4102

Princess Alexandra Hospital, Brisbane

5035

SA Endocrine Research, Keswick

5046

Southern Adelaide Diabetes and Endocrine Services, Adelaide

8011

New Zealand Clinical Research (NZCR), Christchurch

Unknown

The AIM Centre (Hunter Diabetes Centre), Merewether

0932

PCRN Silverdale Medical Centre, Silverdale

All Listed Sponsors

lead

Serodus AS

INDUSTRY